cb-5083 Search Results


cb 5083  (MedChemExpress)
95
MedChemExpress cb 5083
Cb 5083, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cb 5083/product/MedChemExpress
Average 95 stars, based on 1 article reviews
cb 5083 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
cb 5083  (R&D Systems)
94
R&D Systems cb 5083
Cb 5083, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cb 5083/product/R&D Systems
Average 94 stars, based on 1 article reviews
cb 5083 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
cb 5083  (Selleck Chemicals)
94
Selleck Chemicals cb 5083
Cb 5083, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cb 5083/product/Selleck Chemicals
Average 94 stars, based on 1 article reviews
cb 5083 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
cb 5083  (TargetMol)
94
TargetMol cb 5083
Cb 5083, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cb 5083/product/TargetMol
Average 94 stars, based on 1 article reviews
cb 5083 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
cb-1158  (MedKoo Inc)
90
MedKoo Inc cb-1158
Cb 1158, supplied by MedKoo Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cb-1158/product/MedKoo Inc
Average 90 stars, based on 1 article reviews
cb-1158 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
chemical compound, drug scio-469  (Cayman Chemical)
90
Cayman Chemical chemical compound, drug scio-469
Chemical Compound, Drug Scio 469, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chemical compound, drug scio-469/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
chemical compound, drug scio-469 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
active compound cb-5083  (Cleave Biosciences)
90
Cleave Biosciences active compound cb-5083
Active Compound Cb 5083, supplied by Cleave Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/active compound cb-5083/product/Cleave Biosciences
Average 90 stars, based on 1 article reviews
active compound cb-5083 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cdc48 inhibitor cb5083  (ApexBio)
90
ApexBio cdc48 inhibitor cb5083
Cdc48 Inhibitor Cb5083, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdc48 inhibitor cb5083/product/ApexBio
Average 90 stars, based on 1 article reviews
cdc48 inhibitor cb5083 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cb5083  (BioCat GmbH)
90
BioCat GmbH cb5083
Cb5083, supplied by BioCat GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cb5083/product/BioCat GmbH
Average 90 stars, based on 1 article reviews
cb5083 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cb5083 (15-25 mg/kg/day)  (Charles River Laboratories)
90
Charles River Laboratories cb5083 (15-25 mg/kg/day)
New strategies to target VCP and increase RAI uptake. A, Overview of drug development approaches used to target VCP or its co-factor NPL4 and enhance NIS function. B, RAI uptake in TPC-1-NIS cells treated with <t>CB5083</t> at indicated doses for 24 hr. See also Supp Fig. S2A and S2B. C, RAI uptake in human primary thyrocytes treated with CB5083 or CB5339 at indicated dose. ( left ) Schematic depicting the culturing of human primary thyrocytes and RAI uptake. Created with BioRender.com. D, Modelling the binding of clotrimazole, compound C11 and compound C17 to VCP. Dashed lines represent predicted hydrogen bonds with residues (Q494, E498) in the allosteric binding pocket of VCP. ( left ) Chemical structure of clotrimazole highlighting modifications made at the chloro-substituted aryl ring (R 1 ), imidazole ring (R 2 ) and two aryl substituent groups (R 3 ). E, RAI uptake in TPC-1-NIS cells treated with 21 compounds (C1-C21; 12 hr) in combination with SAHA (24 hr) versus clotrimazole (CLOT, C6) + SAHA. Dashed line represents normalised RAI uptake using CLOT in combination with SAHA. See also Supp Fig. S3G and Supp Table S1. F, Heat map depicting mean RAI uptake in TPC-1-NIS and 8505C-NIS cells treated with 21 compounds versus clotrimazole (C6) alone ( lower ) or in combination with SAHA ( upper ). See also Supp Table S1. G, RAI uptake in TPC-1-NIS cells treated with 4 compounds (C22-C25) in combination with SAHA versus SAHA alone. Dashed line represents RAI uptake using SAHA alone. See also Supp Fig. S4. Data presented as mean ± S.E.M., one-way ANOVA followed by Dunnett’s post hoc test (ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001), or unpaired two-tailed t-test ( # P < 0.05).
Cb5083 (15 25 Mg/Kg/Day), supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cb5083 (15-25 mg/kg/day)/product/Charles River Laboratories
Average 90 stars, based on 1 article reviews
cb5083 (15-25 mg/kg/day) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cb-5083  (Fisher Scientific)
90
Fisher Scientific cb-5083
New strategies to target VCP and increase RAI uptake. A, Overview of drug development approaches used to target VCP or its co-factor NPL4 and enhance NIS function. B, RAI uptake in TPC-1-NIS cells treated with <t>CB5083</t> at indicated doses for 24 hr. See also Supp Fig. S2A and S2B. C, RAI uptake in human primary thyrocytes treated with CB5083 or CB5339 at indicated dose. ( left ) Schematic depicting the culturing of human primary thyrocytes and RAI uptake. Created with BioRender.com. D, Modelling the binding of clotrimazole, compound C11 and compound C17 to VCP. Dashed lines represent predicted hydrogen bonds with residues (Q494, E498) in the allosteric binding pocket of VCP. ( left ) Chemical structure of clotrimazole highlighting modifications made at the chloro-substituted aryl ring (R 1 ), imidazole ring (R 2 ) and two aryl substituent groups (R 3 ). E, RAI uptake in TPC-1-NIS cells treated with 21 compounds (C1-C21; 12 hr) in combination with SAHA (24 hr) versus clotrimazole (CLOT, C6) + SAHA. Dashed line represents normalised RAI uptake using CLOT in combination with SAHA. See also Supp Fig. S3G and Supp Table S1. F, Heat map depicting mean RAI uptake in TPC-1-NIS and 8505C-NIS cells treated with 21 compounds versus clotrimazole (C6) alone ( lower ) or in combination with SAHA ( upper ). See also Supp Table S1. G, RAI uptake in TPC-1-NIS cells treated with 4 compounds (C22-C25) in combination with SAHA versus SAHA alone. Dashed line represents RAI uptake using SAHA alone. See also Supp Fig. S4. Data presented as mean ± S.E.M., one-way ANOVA followed by Dunnett’s post hoc test (ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001), or unpaired two-tailed t-test ( # P < 0.05).
Cb 5083, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cb-5083/product/Fisher Scientific
Average 90 stars, based on 1 article reviews
cb-5083 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
cb-5083  (Promega)
90
Promega cb-5083
New strategies to target VCP and increase RAI uptake. A, Overview of drug development approaches used to target VCP or its co-factor NPL4 and enhance NIS function. B, RAI uptake in TPC-1-NIS cells treated with <t>CB5083</t> at indicated doses for 24 hr. See also Supp Fig. S2A and S2B. C, RAI uptake in human primary thyrocytes treated with CB5083 or CB5339 at indicated dose. ( left ) Schematic depicting the culturing of human primary thyrocytes and RAI uptake. Created with BioRender.com. D, Modelling the binding of clotrimazole, compound C11 and compound C17 to VCP. Dashed lines represent predicted hydrogen bonds with residues (Q494, E498) in the allosteric binding pocket of VCP. ( left ) Chemical structure of clotrimazole highlighting modifications made at the chloro-substituted aryl ring (R 1 ), imidazole ring (R 2 ) and two aryl substituent groups (R 3 ). E, RAI uptake in TPC-1-NIS cells treated with 21 compounds (C1-C21; 12 hr) in combination with SAHA (24 hr) versus clotrimazole (CLOT, C6) + SAHA. Dashed line represents normalised RAI uptake using CLOT in combination with SAHA. See also Supp Fig. S3G and Supp Table S1. F, Heat map depicting mean RAI uptake in TPC-1-NIS and 8505C-NIS cells treated with 21 compounds versus clotrimazole (C6) alone ( lower ) or in combination with SAHA ( upper ). See also Supp Table S1. G, RAI uptake in TPC-1-NIS cells treated with 4 compounds (C22-C25) in combination with SAHA versus SAHA alone. Dashed line represents RAI uptake using SAHA alone. See also Supp Fig. S4. Data presented as mean ± S.E.M., one-way ANOVA followed by Dunnett’s post hoc test (ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001), or unpaired two-tailed t-test ( # P < 0.05).
Cb 5083, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cb-5083/product/Promega
Average 90 stars, based on 1 article reviews
cb-5083 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


New strategies to target VCP and increase RAI uptake. A, Overview of drug development approaches used to target VCP or its co-factor NPL4 and enhance NIS function. B, RAI uptake in TPC-1-NIS cells treated with CB5083 at indicated doses for 24 hr. See also Supp Fig. S2A and S2B. C, RAI uptake in human primary thyrocytes treated with CB5083 or CB5339 at indicated dose. ( left ) Schematic depicting the culturing of human primary thyrocytes and RAI uptake. Created with BioRender.com. D, Modelling the binding of clotrimazole, compound C11 and compound C17 to VCP. Dashed lines represent predicted hydrogen bonds with residues (Q494, E498) in the allosteric binding pocket of VCP. ( left ) Chemical structure of clotrimazole highlighting modifications made at the chloro-substituted aryl ring (R 1 ), imidazole ring (R 2 ) and two aryl substituent groups (R 3 ). E, RAI uptake in TPC-1-NIS cells treated with 21 compounds (C1-C21; 12 hr) in combination with SAHA (24 hr) versus clotrimazole (CLOT, C6) + SAHA. Dashed line represents normalised RAI uptake using CLOT in combination with SAHA. See also Supp Fig. S3G and Supp Table S1. F, Heat map depicting mean RAI uptake in TPC-1-NIS and 8505C-NIS cells treated with 21 compounds versus clotrimazole (C6) alone ( lower ) or in combination with SAHA ( upper ). See also Supp Table S1. G, RAI uptake in TPC-1-NIS cells treated with 4 compounds (C22-C25) in combination with SAHA versus SAHA alone. Dashed line represents RAI uptake using SAHA alone. See also Supp Fig. S4. Data presented as mean ± S.E.M., one-way ANOVA followed by Dunnett’s post hoc test (ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001), or unpaired two-tailed t-test ( # P < 0.05).

Journal: bioRxiv

Article Title: Dual agonism of sodium iodide symporter function in vivo

doi: 10.1101/2024.02.27.582332

Figure Lengend Snippet: New strategies to target VCP and increase RAI uptake. A, Overview of drug development approaches used to target VCP or its co-factor NPL4 and enhance NIS function. B, RAI uptake in TPC-1-NIS cells treated with CB5083 at indicated doses for 24 hr. See also Supp Fig. S2A and S2B. C, RAI uptake in human primary thyrocytes treated with CB5083 or CB5339 at indicated dose. ( left ) Schematic depicting the culturing of human primary thyrocytes and RAI uptake. Created with BioRender.com. D, Modelling the binding of clotrimazole, compound C11 and compound C17 to VCP. Dashed lines represent predicted hydrogen bonds with residues (Q494, E498) in the allosteric binding pocket of VCP. ( left ) Chemical structure of clotrimazole highlighting modifications made at the chloro-substituted aryl ring (R 1 ), imidazole ring (R 2 ) and two aryl substituent groups (R 3 ). E, RAI uptake in TPC-1-NIS cells treated with 21 compounds (C1-C21; 12 hr) in combination with SAHA (24 hr) versus clotrimazole (CLOT, C6) + SAHA. Dashed line represents normalised RAI uptake using CLOT in combination with SAHA. See also Supp Fig. S3G and Supp Table S1. F, Heat map depicting mean RAI uptake in TPC-1-NIS and 8505C-NIS cells treated with 21 compounds versus clotrimazole (C6) alone ( lower ) or in combination with SAHA ( upper ). See also Supp Table S1. G, RAI uptake in TPC-1-NIS cells treated with 4 compounds (C22-C25) in combination with SAHA versus SAHA alone. Dashed line represents RAI uptake using SAHA alone. See also Supp Fig. S4. Data presented as mean ± S.E.M., one-way ANOVA followed by Dunnett’s post hoc test (ns, not significant; * P < 0.05; ** P < 0.01; *** P < 0.001), or unpaired two-tailed t-test ( # P < 0.05).

Article Snippet: CB5083 (15-25 mg/kg/day) was given to male BALB/c mice (8-10 weeks of age, n = 3 animals/group, Charles River Laboratories) by oral gavage (OG) administration for 4 days prior to IV administration of 99m Tc.

Techniques: Binding Assay, Two Tailed Test